Literature DB >> 17644748

Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.

Geoffrey Chan, Monika Pilichowska.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17644748     DOI： 10.1182/blood-2007-01-069856

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

Review 2.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

3.  Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.

Authors:  Rami S Komrokji; Eric Padron; Daohai Yu; William J Fulp; Yuraima Rodriguez; Sara Tinsley; Alan F List; Jeffrey E Lancet
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

Review 4.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

5.  Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing.

Authors:  Eric B Haura; Uwe Rix
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

6.  A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Authors:  Daniel J Deangelo; Donna Neuberg; Philip C Amrein; Jacob Berchuck; Martha Wadleigh; L Andres Sirulnik; Ilene Galinsky; Todd Golub; Kimberly Stegmaier; Richard M Stone
Journal:  Leuk Res       Date:  2013-11-05       Impact factor: 3.156

7.  Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Authors:  Elodie Lainey; Marie Sébert; Sylvain Thépot; Marie Scoazec; Cyrielle Bouteloup; Carole Leroy; Stéphane De Botton; Lorenzo Galluzzi; Pierre Fenaux; Guido Kroemer
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

8.  Proteomic and genetic approaches identify Syk as an AML target.

Authors:  Cynthia K Hahn; Jacob E Berchuck; Kenneth N Ross; Rose M Kakoza; Karl Clauser; Anna C Schinzel; Linda Ross; Ilene Galinsky; Tina N Davis; Serena J Silver; David E Root; Richard M Stone; Daniel J DeAngelo; Martin Carroll; William C Hahn; Steven A Carr; Todd R Golub; Andrew L Kung; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

9.  EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.

Authors:  Elodie Lainey; Alice Wolfromm; Abdul Qader Sukkurwala; Jean-Baptiste Micol; Pierre Fenaux; Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-08-13       Impact factor: 4.534

10.  Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.

Authors:  Michelle Degnin; Anupriya Agarwal; Katherine Tarlock; Soheil Meshinchi; Brian J Druker; Cristina E Tognon
Journal:  J Pediatr Hematol Oncol       Date:  2017-10       Impact factor: 1.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.